Published : 21 May 2024
NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, has engaged Aagami, Inc. for business development, specifically to seek licensing and partnering opportunities for their assets and platform technology.
The Company is currently seeking licensing and partnering opportunities for its key asset, NV-387, and its key NanoViricides™ platform technology. The Company has engaged Aagami, to help with these efforts for the regions of India and Japan, noting the Aagami’s strength and specialty in these regions for licensing and partnering endeavors.
NV-387 has successfully completed a Phase I human clinical trial in healthy subjects.
No adverse events were reported even at the highest dose levels tested in the single-ascending dose or the multiple-ascending dose cohorts in the clinical trial.
Two oral formulations of NV-387, (i) Oral Syrup, and (ii) Oral Gummies were tested in this clinical trial, which has been described in more details in NanoViricides prior press releases.
NV-387 is now ready for Phase II clinical trials in any of its multiple indications.
NV-387 is a unique host-mimetic, direct-acting, ultra-broad-spectrum antiviral nanomedicine based on our NanoViricides platform technology. NV-387 is a first-in-class drug that acts by a novel mechanism of action.
Additionally, NanoViricides have developed a formulation, Solution for Injection, Infusion, and Inhalation, for the treatment of severe, hospitalized cases.
NV-387 could be a single drug to treat all of the "tripledemic" viruses, a "holy grail" of development of antiviral therapeutics. Its observed antiviral spectrum in cell culture and animal studies includes the Coronavirus family, including SARS-CoV-2 (COVID, Long COVID), RSV, Influenza A (potentially including H5N1 "Bird Flu"), as well as Smallpox/Mpox.
We believe that NV-387 is a revolutionary ultra-broad-spectrum antiviral drug with a strong potential to transform treatment of viral infections just as the broad-spectrum antibiotic, penicillin, transformed the treatment of bacterial diseases.
"Engaging Aagami gives a significant boost to our licensing and partnering efforts, while at the same time substantially freeing up our executives and staff to focus more strongly on further development of our multiple drugs and the NanoViricides platform through clinical trials," said Anil R. Diwan, PhD, President and Executive Chairman of NanoViricides.
Aagami is excited to support and contribute in Nanoviricides’ success by bringing them Licensing and Partnering deals.
Please see Nanoviricides press release at https://www.nanoviricides.com
If you would like to know more about this partnering opportunity, please contact us at godwyn@aagami.com or dinesh@aagami.com